Neurosurgery/Brain and Spinal Injury Studies

If you think you may qualify for one of these studies, please contact CNI’s Research Department at 303-806-7423. 

Detecting Behavioral Goals from EEG Brain Waves: Parkinson’s disease interferes with starting tasks (such as walking) and switching between tasks. Parkinson’s disease also interferes with switching from one thought to another. This “switching” brain function is located in the frontal lobe, a region of the brain directly connected to areas treated with Deep Brain Stimulation. We strive to understand brain functions involved in this mental flexibility to quickly switch from one task to another. Adults with and without movement disorders such as Parkinson’s disease and Essential Tremor are eligible to participate. While wearing an EEG cap to record brain waves, participants will be asked to perform simple tasks that involve moving a part of the body, speaking, writing, and switching. Research sessions will last 2 hours. Put your mental flexibility to the test!
Principal Investigator: Adam Hebb, MD, FRCSC

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Injection in Adult Subjects with Acute Spinal Cord Injury: To assess the improvement of 2 or more motor levels in SUN13837 treated spinal cord injured subjects versus placebo treated controls.
eligibility and information

A Multi-Center Prospective Study Evaluating Aspen™ Spinous Process Fixation System for use in Posterolateral Fusion (PLF) in Patients with Spondylolisthesis

Intrepid: Implantable Neurostimulator for the Treatment of Parkinson’s disease: To evaluate the safety and effectiveness of the Boston Scientific implantable deep brain stimulation (DBS) Vercise™ system for bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy for improving the number of waking hours per day with good symptom control and no troublesome dyskinesia (ON time) in adults with advanced, levodopa-responsive bilateral Parkinson’s disease (PD) which is not adequately controlled with medication.

DCVax-L: A Phase III clinical trial evaluating DCVax®-L, autologous dendritic cells (DC) pulsed with tumor lysate antigen for the treatment of glioblastoma multiforme (GBM). To compare progression free survival (PFS) between patients in the DCVax-L cohort and patients in the placebo cohort in patients with no evidence of disease progression at baseline.


Colorado Neurological Insitute